Skip to main content
. 2014 Jan 31;8:8. doi: 10.3389/fnins.2014.00008

Figure 3.

Figure 3

Effects of DORA, suvorexant, on basal sleep/wakefulness states in C57BL/6 mice (n = 7–9/group) after administration at ZT12. Suvorexant (10 and 30 mg/kg) and methylcellulose as control were administered per os at the start of the dark period (t = 0, ZT12). (A–C) Total time spent in wakefulness (A), NREM sleep (B) and REM sleep (C) in 6 h time windows over 24 h. (D–F) Mean duration of wakefulness (D), NREM sleep (E) and REM sleep (F) in 6 h time windows over 24 h. Data for the dark and light periods are displayed with light gray and white backgrounds, respectively. (G,H). Latency to NREM sleep (time to appearance of first NREM sleep after administration) (G) and REM sleep latency (time to appearance of first REM sleep after administration) (H) during dark period. Results are expressed in minutes and presented as mean ± s.e.m. (I) EEG power density during NREM sleep for 3 h after administration shown as mean percentage of total EEG power. The delta range (0.75–4 Hz) is indicated by the black bars and the theta range (6–9 Hz) by the gray bars. *p < 0.05 for 10 mg/kg suvorexant, +p < 0.05 for 30 mg/kg suvorexant vs. control.